Wagner J D, Schauwecker D S, Davidson D, Wenck S, Jung S H, Hutchins G
Indiana University School of Medicine, Department of Surgery, Indiana University-Purdue University at Indianapolis, Indianapolis, IN 46202, USA.
J Surg Oncol. 2001 Aug;77(4):237-42. doi: 10.1002/jso.1102.
The purpose of this study is to determine the tumor volume threshold for successful positron emission tomography (PET) imaging of melanoma nodal metastases.
Review of a clinical series of patients who had FDG-PET imaging of regional lymph node basins followed by lymphadenectomy. Lymph node tumor volumes were calculated from direct measurements of metastatic nodule(s) in formalin fixed specimens. PET scan interpretations were correlated with histology to determine sensitivity. Sensitivity was correlated with the aggregate lymph node tumor volume in the nodal basin and with AJCC stage group.
Forty-five patients with 49 pathologically positive regional nodal basins comprised the study group. Median total basin tumor volume was 28.3 mm(3)(range 0.004-22,879 mm(3)). FDG-PET sensitivity for detection of all tumor volumes was 0.49. The observed 90% sensitivity threshold for detection of nodal metastases was > or = 78 mm(3). PET sensitivity was 0.14 for detection of tumor volumes < 78 mm(3). PET sensitivity differed by prescan AJCC stage: I-0.0; II-0.24; III-0.81; IV-1.0 (P < 0.001).
FDG-PET reliably detects lymph node tumor deposits greater than approximately 80 mm(3) volume, but sensitivity falls rapidly below this. This amount of tumor is most likely to occur in patients with AJCC stage III or IV disease.
本研究旨在确定黑色素瘤淋巴结转移灶成功进行正电子发射断层扫描(PET)成像的肿瘤体积阈值。
回顾一组对区域淋巴结区域进行氟代脱氧葡萄糖(FDG)-PET成像后行淋巴结切除术的临床患者。通过对福尔马林固定标本中转移结节的直接测量计算淋巴结肿瘤体积。将PET扫描结果与组织学结果相关联以确定敏感性。敏感性与淋巴结区域的总淋巴结肿瘤体积以及美国癌症联合委员会(AJCC)分期组相关。
45例患者的49个病理证实的区域淋巴结区域构成研究组。淋巴结区域的总肿瘤体积中位数为28.3立方毫米(范围0.004 - 22879立方毫米)。FDG-PET对所有肿瘤体积的检测敏感性为0.49。检测淋巴结转移灶的观察到的90%敏感性阈值为≥78立方毫米。对于肿瘤体积<78立方毫米的检测,PET敏感性为0.14。PET敏感性因扫描前AJCC分期而异:I期-0.0;II期-0.24;III期-0.81;IV期-1.0(P<0.001)。
FDG-PET能够可靠地检测出体积大于约80立方毫米的淋巴结肿瘤沉积物,但在此体积以下敏感性迅速下降。这种肿瘤量最可能出现在AJCC III期或IV期疾病患者中。